The observation regarding the association of CCR5 with RRMS is consistent with a previous study revealing that patients with the defective CCR5 receptor (CCR5 Δ32 deletion) have prolonged relapse free periods, but the long term prognosis of MS did not seem to correlate with the CCR5 Δ32 genotype [55]. Here, CCR5 is linked to myeloid sarcoma.